Terms: = Lymphoma AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
234 results:
1. Analysis and Investigation of Bioinformatics and Epigenetics Reveal the Underlying Mechanisms by which FLOT2 Modulates the Progression of Diffuse Large B-cell lymphoma.
Zhang Y; Chen Y; Guo Q; Zhang Y; Liu A
Discov Med; 2024 Mar; 36(182):621-631. PubMed ID: 38531803
[TBL] [Abstract] [Full Text] [Related]
2. [Progress in treatment of primary mediastinal large B-cell lymphoma].
Chen LW; Li JY; Fan L
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):98-102. PubMed ID: 38527847
[TBL] [Abstract] [Full Text] [Related]
3. Differential Upregulation of Th1/Th17-Associated Proteins and PD-L1 in Granulomatous Mycosis Fungoides.
Marques-Piubelli ML; Navarrete J; Ledesma DA; Hudgens CW; Lazcano RN; Alani A; Huen A; Duvic M; Nagarajan P; Aung PP; Wistuba II; Curry JL; Miranda RN; Torres-Cabala CA
Cells; 2024 Feb; 13(5):. PubMed ID: 38474383
[TBL] [Abstract] [Full Text] [Related]
4. Correlation between pd-1 and sPD-L1 expression levels in peripheral blood of DLBCL patients and their clinicopathological characteristics.
Wang L; Cao C; Qiu J; Zhang J; He Q; Song L; Xie L; Ma J
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):44-50. PubMed ID: 38430041
[TBL] [Abstract] [Full Text] [Related]
5. Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities.
Roider T; Baertsch MA; Fitzgerald D; Vöhringer H; Brinkmann BJ; Czernilofsky F; Knoll M; Llaó-Cid L; Mathioudaki A; Faßbender B; Herbon M; Lautwein T; Bruch PM; Liebers N; Schürch CM; Passerini V; Seifert M; Brobeil A; Mechtersheimer G; Müller-Tidow C; Weigert O; Seiffert M; Nolan GP; Huber W; Dietrich S
Nat Cell Biol; 2024 Mar; 26(3):478-489. PubMed ID: 38379051
[TBL] [Abstract] [Full Text] [Related]
6. Genomic features reveal potential benefit of adding anti-pd-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma.
Chen Z; Huang H; Huang H; Yu L; Weng H; Xiao J; Zou L; Zhang H; Liang C; Zhou H; Guo H; Wang Z; Li Z; Wu T; Zhang H; Wu H; Peng Z; Zhai L; Chen X; Liang Y; Hong H; Lin T
Leukemia; 2024 Apr; 38(4):829-839. PubMed ID: 38378844
[TBL] [Abstract] [Full Text] [Related]
7. Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma.
Liu C; Zhou C; Xia W; Zhou Y; Qiu Y; Weng J; Zhou Q; Chen W; Wang YN; Lee HH; Wang SC; Kuang M; Yu D; Ren N; Hung MC
Nat Commun; 2024 Feb; 15(1):1009. PubMed ID: 38307859
[TBL] [Abstract] [Full Text] [Related]
8. Tumoural Pellino-1 expression and Pellino-1-expressive cytotoxic T-cells are associated with poor prognosis in diffuse large B-cell lymphoma.
Shin SJ; Ko J; Hwang HS; Huh J; Lee CW; Lee JK; Go H
Pathology; 2024 Apr; 56(3):374-381. PubMed ID: 38296676
[TBL] [Abstract] [Full Text] [Related]
9. pd-1 blockade combined with decitabine to treat refractory peripheral T-cell lymphoma not otherwise specified: A case report and review of literature.
Han X; Liu X; Zhang C; Wen Q; Zhang X
J Cancer Res Ther; 2023 Dec; 19(6):1680-1684. PubMed ID: 38156938
[TBL] [Abstract] [Full Text] [Related]
10. Tumor microenvironment in Hodgkin lymphoma: novel prognostic factors for assessing disease evolution.
Turbatu A; Dobrea C; Stoian M; Barta CT; Halcu G; Birceanu A; Bordea AM; Ghimici CG; Oprea MM; Neacșu LD; Lupu AR; Coliță A
J Med Life; 2023 Aug; 16(8):1201-1210. PubMed ID: 38024830
[TBL] [Abstract] [Full Text] [Related]
11. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
12. A novel telomere-related genes model for predicting prognosis and treatment responsiveness in diffuse large B-cell lymphoma.
Zhao Z; Shen X; Zhao S; Wang J; Tian Y; Wang X; Tang B
Aging (Albany NY); 2023 Nov; 15(22):12927-12951. PubMed ID: 37976136
[TBL] [Abstract] [Full Text] [Related]
13. Higher pd-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia.
Huang S; Zhao Y; Lai W; Tan J; Zheng X; Zha X; Li Y; Chen S
Cancer Biol Ther; 2023 Dec; 24(1):2278229. PubMed ID: 37962843
[TBL] [Abstract] [Full Text] [Related]
14. Expression of pd-1/PD-L1 in peripheral blood and tumor tissues of patients with classical Hodgkin's lymphoma.
Feng X; Luo X; Yang Y; Fan Y; Ye Q
Medicine (Baltimore); 2023 Nov; 102(44):e35757. PubMed ID: 37933048
[TBL] [Abstract] [Full Text] [Related]
15. Blockade of pd-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells.
Ma J; Yan S; Zhao Y; Yan H; Zhang Q; Li X
Front Immunol; 2023; 14():1265255. PubMed ID: 37841254
[TBL] [Abstract] [Full Text] [Related]
16. Tislelizumab augment the efficacy of CD19/22 dual-targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B-cell non-Hodgkin lymphoma.
Zhang Y; Geng H; Zeng L; Li J; Yang Q; Jia S; Zong X; Cai W; Liu S; Lu Y; Yu L; Li C; Wu D
Hematol Oncol; 2024 Jan; 42(1):e3227. PubMed ID: 37776326
[TBL] [Abstract] [Full Text] [Related]
17. Clinical implications of aberrant pd-1 expression for acute leukemia prognosis.
Ruan Y; Wang J; Zhang Q; Wang H; Li C; Xu X; Zhai Z
Eur J Med Res; 2023 Sep; 28(1):383. PubMed ID: 37759316
[TBL] [Abstract] [Full Text] [Related]
18. pd-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma.
Wartewig T; Daniels J; Schulz M; Hameister E; Joshi A; Park J; Morrish E; Venkatasubramani AV; Cernilogar FM; van Heijster FHA; Hundshammer C; Schneider H; Konstantinidis F; Gabler JV; Klement C; Kurniawan H; Law C; Lee Y; Choi S; Guitart J; Forne I; Giustinani J; Müschen M; Jain S; Weinstock DM; Rad R; Ortonne N; Schilling F; Schotta G; Imhof A; Brenner D; Choi J; Ruland J
Nat Cancer; 2023 Oct; 4(10):1508-1525. PubMed ID: 37723306
[TBL] [Abstract] [Full Text] [Related]
19. Accelerated Chronic Lymphocytic Leukemia and Richter Transformation in the Era of Novel Agents.
Levy Yurkovski I; Tadmor T
Acta Haematol; 2024; 147(1):73-83. PubMed ID: 37666234
[TBL] [Abstract] [Full Text] [Related]
20. Angioimmunoblastic T-cell lymphoma: Novel recurrent mutations and prognostic biomarkers by cell-free DNA profiling.
Zhang C; Mou B; Xu J; Wang J; Liu Q; Yang Y; Tang W; Zhong X; Xu C
Br J Haematol; 2023 Dec; 203(5):807-819. PubMed ID: 37646306
[TBL] [Abstract] [Full Text] [Related]
[Next]
